04:00 PM EDT, 05/20/2024 (MT Newswires) -- Novo Nordisk's ( NVO ) Wegovy may be more effective in reducing the weight of patients with certain genes, Reuters reported Monday, citing a study by researchers at the Digestive Disease Week meeting.

The study showed patients with genetic variants linked to "hungry gut" condition had a 95% likelihood to show a strong response to the treatment, according to the report.

Novo Nordisk ( NVO ) did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 132.99, Change: +1.10, Percent Change: +0.83